Prophase

ProPhase Labs Unveils Project ZenQ-AI

Retrieved on: 
Tuesday, April 16, 2024
Project, Cancer, Genomics, Whole genome sequencing, Safety, AI, Esophageal cancer, Nebula Genomics, Genetics, Machine learning, WGS, Doctor of Philosophy, DNA, SNP, Therapy, ADC, Marker beacon, Prophase, NVIDIA, Genome, EAC, Database, Diagnosis, CIO, Biomarker, Algorithm, Spacecraft, Medical device

Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (WGS) spanning more than 130 countries, and equivalent to roughly 150 million ancestry SNP-based tests. Whole Genome Sequencing (WGS) offers an exhaustive exploration of an individual’s entire DNA, capturing all three billion base pairs for a complete and detailed genetic blueprint. This comprehensive approach contrasts sharply with SNP tests, which target specific genetic variations at known locations, typically analyzing between 100,000 to 1 million specific points. With WGS providing up to 30,000 times more genetic data than SNP testing, our service delivers unparalleled precision in personalized medicine and genetic research, far beyond the scope of standard SNP testing. Along with the data gathered from the Company’s BE-Smart Test for esophageal adenocarcinoma (EAC), the platform is being utilized to create algorithms that identify possible antibody drug conjugate (ADC) candidates for new cancer therapeutics.

Key Points: 
  • Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI.
  • "The power of Project ZenQ-AI not only stems from cutting-edge AI technology, but also the vast and growing genomic database that we’ve curated and continue to grow," explained Ted Karkus, CEO at ProPhase Labs.
  • To support the computational demands of Project ZenQ-AI, ProPhase Labs is utilizing a dual-approach in technology.
  • ProPhase Labs invites collaboration from across the scientific and medical communities to join in this groundbreaking initiative.

ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024

Retrieved on: 
Wednesday, April 10, 2024
Mayo Clinic, Cancer, Genomics, Hospital, Esophageal cancer, Proteomics, Insurance, Partnership, Doctor of Philosophy, Documentation, Clinical professor, Patient, CPT, Prophase, Endoscopy, EAC, Health, GERD, Risk assessment, Medical imaging

Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection.

Key Points: 
  • Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection.
  • Early detection offers patients the opportunity for more favorable outcomes and a brighter, healthier future.
  • ProPhase intends to pursue and seeks to capture a significant share of a multi-billion-dollar market for EAC diagnostics.
  • Obtaining CPT codes is important for billing purposes, enabling ProPhase Labs to bill for providing the test services and receive reimbursement from insurance companies.

ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives

Retrieved on: 
Friday, March 15, 2024
Research, WGS, Automation, Genomics, Absorption, Health, Development, Growth, Exercise, Nebula Genomics, COVID-19, Patient, PMI, RNA, Sale, Acquisition, Public expenditure, Food, Engineering, Insurance, Protein, Diagnosis, RNA-Seq, Omicron, Prophase, HRSA, Whole genome sequencing, Marketing, FDA, Genetic counseling, Cryptocurrency

Garden City, NY, March 15, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today reported its financial and operational results for the full-year ended December 31, 2023.

Key Points: 
  • With this significant repositioning completed, Nebula Genomics can now deliver low-cost, high-precision genomic diagnostics across North America and the global market.
  • This agreement presents the possibility for significant expansion of its global footprint and paves the way for prospective future revenue streams.
  • Research and development costs for the year ended December 31, 2023 and 2022 were $1.4 million and $0.7 million, respectively.
  • Diluted earnings per share for the years ended December 31, 2023 and 2022 were $(0.98) and $1.02, respectively.

ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART

Retrieved on: 
Tuesday, February 20, 2024
Marie Cassidy, Prophase, Barrett's esophagus, Patent, Gastroenterology, LDT, Risk, Cancer, GI, Mayo Clinic, The Wall Street Journal, Clinical professor, Patient, Carcinogenesis, Clinical trial, Genomics, Esophageal cancer, Plague

This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.

Key Points: 
  • This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.
  • If the clinical trial results are successful, the Company will be aiming for commercial launch during 2024.
  • Recently, an additional 139 specimens were analyzed in collaboration with The Mayo Clinic, for the purposes of assessing the test's precision and reliability in identifying esophageal adenocarcinoma risk.
  • - The test has demonstrated molecular precision in excess of 99%1, which is a remarkably precise accomplishment in cancerous tissue analysis.

ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir

Retrieved on: 
Wednesday, February 14, 2024
Prophase, COVID-19, Marketing, OTC, Food, Viral, Patient, Genomics, Immunity, Vaccine

Garden City, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced positive preliminary results from its Equivir dietary supplement comprehensive trial. Preliminary results indicate that this innovative OTC dietary supplement has the potential to support and maintain immunity, which – if confirmed at the end of the clinical trial program – may help reduce both the frequency and severity of upper respiratory illnesses including the common cold, flu, and Covid-19.

Key Points: 
  • Commercialization of Equivir anticipated after second trial is completed in Q2, 2024
    Garden City, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced positive preliminary results from its Equivir dietary supplement comprehensive trial.
  • Each study enrolls 150 participants, randomly assigned to receive either Equivir or a placebo, with their health monitored over a 180-day period.
  • Preliminary results are as follows:
    Overall, in the initial 150 patient group there were approximately 46 incidences of upper respiratory viral infections.
  • Equivir is being developed with plans to market as an OTC dietary supplement.

Sidus Space Appoints Bill White as Chief Financial Officer

Retrieved on: 
Thursday, February 8, 2024
Mobile, Wireless, Technology, Satellite, Telecommunications, Professional Services, Aerospace, Manufacturing, Networks, Internet, Data Analytics, Strategic planning, CFO, White, Growth, Financial management, Prophase

Sidus Space (NASDAQ: SIDU) (the “Company” or “Sidus”), a multi-faceted Space and Data-as-a-Service company, today announced the appointment of Bill White as Chief Financial Officer, effective February 20, 2024.

Key Points: 
  • Sidus Space (NASDAQ: SIDU) (the “Company” or “Sidus”), a multi-faceted Space and Data-as-a-Service company, today announced the appointment of Bill White as Chief Financial Officer, effective February 20, 2024.
  • Mr. White has more than 30 years of experience in financial management, operations, and business development.
  • “I am honored to serve Sidus at this critical time in its growth and evolution and am excited to work with Carol and the management team to capitalize upon the growth opportunities ahead and deliver long-term value for shareholders," said Bill White, incoming Chief Financial Officer.
  • Teresa Burchfield has confirmed her intention to step down as Chief Financial Officer after two years with the Company.

ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics

Retrieved on: 
Tuesday, January 30, 2024
Prophase, Growth, Whole genome sequencing, Therapy, Karkus, Nebula Genomics, Marketing, Genomics, Acquisition, Health, Nebula, WGS

Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.

Key Points: 
  • Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.
  • This fiscal achievement fueled ProPhase's growth and strategic acquisition of Nebula Genomics.
  • In his new role, Karkus aims to amplify the Nebula Genomics business-to-business operations, as well as its exciting direct-to-consumer Whole Genome Sequencing (WGS) model.
  • As ProPhase focuses on its WGS business lines, Karkus’ leadership, energy and vision are expected to be a driving force.

ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024

Retrieved on: 
Thursday, January 4, 2024
Nebula Genomics, CFO, Prophase, Acquisition, Columbia, Genomics, Growth, Acceleration, Therapy, Employment, COVID-19, Property management

Garden City, NY, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jed Latkin, a long-time operations and finance expert, has accepted the role as COO of the parent company.

Key Points: 
  • Mr. Latkin, a Columbia MBA, represented the seller in the Company’s acquisition of the BE-SMART Esophageal Cancer Test.
  • Mr. Latkin has been in the finance and management industry since 1996 and has worked with over 15 pharmaceutical companies over the last ten years alone.
  • “We anticipate an acceleration in growth at both Nebula Genomics and Pharmaloz Manufacturing, as well as commercialization of our BE-SMART esophageal cancer test, during 2024.
  • The options have an exercise price of $6.00 per share and will be exercisable for a period of seven years.

ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2023

Retrieved on: 
Thursday, November 9, 2023
Adjustment, TK, FDA, Genetic counseling, Nebula Genomics, Research, Sale, Genomics, Endoscopy, CDX, FDM, Food, Genetic, Heart, Therapy, Hospital Insurance and Diagnostic Services Act, COVID-19 testing, Three Months, History, Public expenditure, Omicron, Diagnosis, EBITDA, Corporation, Absorption, Genetics, Exercise, Prophase, House, Whole genome sequencing, Internet, Health Resources and Services Administration, COVID-19, Medicine, Marketing, Stella, WGS, CPT, Current Procedural Terminology, Patient, Anesthesia, Automation, Antibiotics, Renewable energy, Mobile phone, Clothing, Life insurance, Security (finance), Fine chemical, Birth control, Auction, Broadcasting, Pharmaceutical industry, Cryptocurrency, Bosc

Garden City, NY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three and nine months ended September 30, 2023.

Key Points: 
  • Three Months Ended September 30, 2023 as compared to the Three Months Ended September 30, 2022.
  • Net revenue for the three months ended September 30, 2023 was $8.4 million as compared to $24.2 million for the three months ended September 30, 2022.
  • Diagnostic services costs for the three months ended September 30, 2023 were $0.1 million compared to $2.4 million for the three months ended September 30, 2022.
  • Adjusted EBITDA loss for the three months ended September 30, 2023 was $(2.5) million compared to adjusted EBITDA income of $6.3 million for the three months ended September 30, 2023.

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into ProPhase Labs, Inc.; Urges ProPhase Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

Retrieved on: 
Saturday, November 4, 2023
Prophase

STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase” or the “Company”) on behalf of the Company’s investors.

Key Points: 
  • STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase” or the “Company”) on behalf of the Company’s investors.
  • ProPhase stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing [email protected] or by filling out a contact from on our website at www.abbottlawyer.com for additional information about this investigation as well as their legal rights and options.
  • Abbott Cooper PLLC is dedicated to shareholders’ rights and empowering shareholders through strategic counsel and legal advocacy.
  • For additional information about Abbott Cooper PLLC, please visit www.abbottlawyer.com .